JPMorgan Chase & Co. reaffirmed their buy rating on shares of Bluebird Bio Inc. (NASDAQ:BLUE) in a research note published on Monday morning.

A number of other research analysts also recently weighed in on BLUE. Jefferies Group set a $80.00 target price on shares of Bluebird Bio and gave the company a buy rating in a research report on Saturday, October 15th. Maxim Group set a $85.00 target price on shares of Bluebird Bio and gave the company a buy rating in a research report on Thursday, September 22nd. Leerink Swann reaffirmed an outperform rating and issued a $67.00 target price on shares of Bluebird Bio in a research report on Thursday, August 4th. Wedbush reaffirmed an outperform rating and issued a $117.00 target price on shares of Bluebird Bio in a research report on Wednesday, August 3rd. Finally, Piper Jaffray Cos. reaffirmed an overweight rating and issued a $95.00 target price on shares of Bluebird Bio in a research report on Friday, November 4th. One analyst has rated the stock with a sell rating, four have given a hold rating and thirteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $86.19.

Bluebird Bio (NASDAQ:BLUE) traded up 6.46% on Monday, hitting $56.00. 282,758 shares of the stock traded hands. Bluebird Bio has a 52 week low of $35.37 and a 52 week high of $95.28. The stock’s market cap is $2.09 billion. The firm’s 50 day moving average is $59.55 and its 200 day moving average is $51.29.

Bluebird Bio (NASDAQ:BLUE) last released its earnings results on Wednesday, November 2nd. The company reported ($2.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.59) by $0.48. The business earned $1.55 million during the quarter, compared to the consensus estimate of $1.82 million. Bluebird Bio had a negative net margin of 3,941.72% and a negative return on equity of 30.79%. The firm’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same period last year, the business posted ($1.18) EPS. Equities analysts anticipate that Bluebird Bio will post ($6.87) earnings per share for the current year.

In other news, insider Eric Sullivan sold 416 shares of the firm’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $67.00, for a total transaction of $27,872.00. Following the completion of the sale, the insider now owns 5,891 shares in the company, valued at approximately $394,697. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 3.50% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Seven Eight Capital LLC bought a new stake in Bluebird Bio during the first quarter worth about $108,000. Quantbot Technologies LP boosted its stake in Bluebird Bio by 431.3% in the second quarter. Quantbot Technologies LP now owns 2,848 shares of the company’s stock worth $123,000 after buying an additional 2,312 shares in the last quarter. First Mercantile Trust Co. bought a new stake in Bluebird Bio during the third quarter worth about $129,000. Sei Investments Co. boosted its stake in Bluebird Bio by 106.7% in the third quarter. Sei Investments Co. now owns 2,515 shares of the company’s stock worth $170,000 after buying an additional 1,298 shares in the last quarter. Finally, Winslow Evans & Crocker Inc. boosted its stake in Bluebird Bio by 170.0% in the third quarter. Winslow Evans & Crocker Inc. now owns 2,700 shares of the company’s stock worth $183,000 after buying an additional 1,700 shares in the last quarter.

About Bluebird Bio

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

5 Day Chart for NASDAQ:BLUE

Receive News & Stock Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related stocks with our FREE daily email newsletter.